| Name | Title | Contact Details |
|---|
VelosBio, Inc. operates as a biotechnology firm specializing in oncology.
Verax Biomedical Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Luzsana Biotechnology™ is a new kind of biotech company with a mission to make innovative medicines available, accessible, and affordable to anyone, anywhere.
Spero is a multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to identifying, developing and commercializing novel treatments focused on unmet needs of patients with multidrug-resistant (MDR) bacterial infections. Spero`s lead product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero`s lead product candidates generated from its Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial infection.
The mission of Proteonomix, Inc. is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.